H2020Индивидуална стипендия2019–2021

TRACE-AD · Tracking the Effects of Amyloid and Tau Pathology on Brain Systems and Cognition in Early Alzheimer’s Disease

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2019-04-01 → 2021-03-31
Финансиране от ЕС: 191 852 €
Участници: 1
Схема: MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Промените в мозъка и паметта при ранна болест на Алцхаймер се проследяват чрез скенерни изследвания и приложения за смартфони. Това помага да се разбере кога точно да се започне терапията и как да се открият хора в начален стадий на заболяването.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Tracking the Effects of Amyloid and Tau Pathology on Brain Systems and Cognition in Early Alzheimer’s Disease

Alzheimer’s disease is a tremendous burden for individual patients, relatives and the health care system. Despite intensive research efforts and drug development, there are still no therapies that have been shown to slow down or stop the disease in a phase 3 trial. So far, most clinical trials have focused on patients in the symptomatic late stages of AD where the neuronal damage is already severe and probably irreversible. Thus, it is imperative to focus on earlier stages of the disease. In early stages, the two hallmark pathologies of Alzheimer’s disease – beta-amyloid and tau – can be found in circumscribed anatomical systems before they eventually affect the entire human brain. Overall, AD pathology leads to changes in brain function, cognitive impairment where the core deficit is memory decline and loss of grey matter. However, due to our limited understanding how AD pathology affects brain and cognitive function early in the disease, it is not known when disease-modifying therapies should target beta-amyloid and/or tau to effectively slow down or even reverse symptoms. Likewise, there is an urgent need for sensitive markers that can identify individuals who are at an early asymptomatic stage, but are likely to deteriorate in the coming years, because such individuals are likely to benefit most from early intervention trials. Finally, we need sensitive markers of treatment response that can indicate the benefit of a treatment. Here we employed the powerful combination of ultrahigh-field magnetic resonance imaging (MRI) with positron emission tomography (PET) and novel memory assessments via smartphones to unravel the early functional, structural and cognitive changes related to A and tau. The aim of the proposal is a more profound understanding of the earliest stages of the disease as well as novel cognitive and imaging markers that improve patient selection and stratification as well as the assessment of treatment response in future clinical AD trials.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Alzheimer’s disease (AD) is a tremendous burden and there are still no therapies available. Most clinical trials have focused on the late disease stages where neuronal damage is already severe and irreversible. To intervene in earlier stages, it is essential to understand how AD pathology affects brain systems early in the disease. Beyond that, we need better markers to identify individuals at an early asymptomatic stage that will likely deteriorate in the coming years as well as measures of treatment response to assess the benefit of a treatment.I focus on two functional brain systems that are critical for memory in humans and are very early affected by AD pathology. With the powerful and novel combination of positron-emission-tomography and ultrahigh-field magnetic resonance imaging, I will unravel the early effects of AD pathology on brain connectivity and activity, grey matter loss and memory function within both brain systems. I will use a pseudo-longitudinal design to study changes in brain system integrity and memory during disease progression in the very early stages of AD. To identify predictive markers of progression, I will use monthly repeated smartphone-based assessments throughout one year to i) define cognitive trajectories of individual memory decline, ii) characterize stage-specific decline rates, and ii) determine the best cognitive and imaging markers for prediction of cognitive decline.Taken together, this proposal will result in a more profound understanding of the earliest stages of AD and provide novel markers that will improve patient selection as well as assessment of treatment response in future clinical AD trials. This will advance the development of new disease-modifying therapies and early clinical diagnosis. Importantly, realizing this proposal will provide critical training of scientific and transferable skills that are required to follow my research interests and to set up my own research group in the future.

Оригинален текст от CORDIS (на английски).

Участници

LUNDS UNIVERSITET · LundКоординаторШвеция